NOVELIX [NOVELIX] vs Entero Healthcare [ENTERO] Detailed Stock Comparison

NOVELIX PHARMACEUTICALS LIMITE

BSE
Loading...

Entero Healthcare Solutions

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: NOVELIX PHARMACEUTICALS LIMITE wins in 7 metrics, Entero Healthcare Solutions wins in 11 metrics, with 1 ties. Entero Healthcare Solutions appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric NOVELIX PHARMACEUTICALS LIMITE Entero Healthcare Solutions Better
P/E Ratio (TTM) 48.76 48.93 NOVELIX PHARMACEUTICALS LIMITE
Price-to-Book Ratio 3.10 3.11 NOVELIX PHARMACEUTICALS LIMITE
Debt-to-Equity Ratio 0.00 24.63 Tie
PEG Ratio 0.17 5.72 NOVELIX PHARMACEUTICALS LIMITE
EV/EBITDA 39.81 28.71 Entero Healthcare Solutions
Profit Margin (TTM) 1.41% 1.87% Entero Healthcare Solutions
Operating Margin (TTM) 2.65% 3.40% Entero Healthcare Solutions
EBITDA Margin (TTM) 2.65% 3.40% Entero Healthcare Solutions
Return on Equity 0.48% 5.36% Entero Healthcare Solutions
Return on Assets (TTM) 0.31% 3.51% Entero Healthcare Solutions
Free Cash Flow (TTM) $-137.91M $-881.80M NOVELIX PHARMACEUTICALS LIMITE
1-Year Return 100.43% -0.41% NOVELIX PHARMACEUTICALS LIMITE
Price-to-Sales Ratio (TTM) 0.91 0.91 NOVELIX PHARMACEUTICALS LIMITE
Enterprise Value $964.62M $58.10B Entero Healthcare Solutions
EV/Revenue Ratio 0.75 0.97 NOVELIX PHARMACEUTICALS LIMITE
Gross Profit Margin (TTM) 3.21% 10.11% Entero Healthcare Solutions
Revenue per Share (TTM) $85 $1,383 Entero Healthcare Solutions
Earnings per Share (Diluted) $1.13 $25.83 Entero Healthcare Solutions
Beta (Stock Volatility) 0.50 -0.79 Entero Healthcare Solutions

NOVELIX PHARMACEUTICALS LIMITE vs Entero Healthcare Solutions Stock Performance Analysis

Loading Price Chart...

NOVELIX
ENTERO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NOVELIX PHARMACEUTICALS LIMITE3.46%-2.57%-4.03%-7.95%-20.39%-13.17%
Entero Healthcare Solutions-2.17%-10.21%-6.57%12.44%9.42%2.02%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NOVELIX PHARMACEUTICALS LIMITE100.43%131.88%131.88%131.88%131.88%131.88%
Entero Healthcare Solutions-0.41%4.02%4.02%4.02%4.02%4.02%

Performance & Financial Health Analysis: NOVELIX PHARMACEUTICALS LIMITE vs Entero Healthcare Solutions

MetricNOVELIXENTERO
Market Information
Market Cap i₹1.16B₹54.69B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i6,32976,067
90 Day Avg. Volume i6,50889,093
Last Close₹54.49₹1,127.40
52 Week Range₹27.94 - ₹70.16₹944.00 - ₹1,390.00
% from 52W High-22.33%-18.89%
All-Time High₹70.16 (Nov 19, 2025)₹1,584.25 (Nov 04, 2024)
% from All-Time High-22.33%-28.84%
Growth Metrics
Quarterly Revenue Growth8.13%0.26%
Quarterly Earnings Growth5.79%0.09%
Financial Health
Profit Margin (TTM) i0.01%0.02%
Operating Margin (TTM) i0.03%0.03%
Return on Equity (TTM) i0.00%0.05%
Debt to Equity (MRQ) i0.0024.63
Cash & Liquidity
Book Value per Share (MRQ)₹17.77₹405.79
Cash per Share (MRQ)₹0.84₹37.37
Operating Cash Flow (TTM) i₹-221,349,560₹-1,784,990,000
Levered Free Cash Flow (TTM) i₹845,200₹948.20M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: NOVELIX PHARMACEUTICALS LIMITE vs Entero Healthcare Solutions

MetricNOVELIX (Apr 24, 2026)ENTERO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i48.7648.93
Forward P/E iN/A28.42
PEG Ratio i0.175.72
Price to Sales (TTM) i0.910.91
Price to Book (MRQ) i3.103.11
Market Capitalization
Market Capitalization i₹1.16B₹54.69B
Enterprise Value i₹964.62M₹58.10B
Enterprise Value Metrics
Enterprise to Revenue i0.750.97
Enterprise to EBITDA i39.8128.71
Risk & Other Metrics
Beta i0.50-0.79
Book Value per Share (MRQ) i₹17.77₹405.79

Financial Statements Comparison: NOVELIX PHARMACEUTICALS LIMITE vs Entero Healthcare Solutions

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNOVELIX (2025)ENTERO (2025)
Revenue/Sales i307.18M50.65B
Cost of Goods Sold i295.74M46.09B
COGS % of Revenue i96.3%91.0%
Gross Profit i11.45M4.56B
Gross Margin i3.7%9.0%
Research & Development iN/AN/A
Operating Income (EBIT) i1.12M1.42B
Operating Margin i0.4%2.8%
EBITDA i1.66M2.07B
EBITDA Margin i0.5%4.1%
Pre-Tax Income i1.23M1.39B
Pre-Tax Income % of Revenue i0.4%2.7%
Income Tax i388,230313.05M
Income Tax % of Revenue i0.1%0.6%
Net Income (Profit) i845,2001.07B
Profit Margin i0.3%2.1%

Balance Sheet & Liquidity Metrics

MetricNOVELIX (2025)ENTERO (2025)
Cash & Equivalents i6.79M2.29B
Total Current Assets i269.33M20.76B
Total Current Assets % of Revenue i87.7%41.0%
Total Current Liabilities i96.67M8.45B
Total Current Liabilities % of Revenue i31.5%16.7%
Long-Term Debt i0670.18M
Long-Term Debt % of Revenue i0.0%1.3%
Total Shareholders Equity i175.39M17.70B
Retained Earnings i-18.76M638.28M
Retained Earnings % of Revenue i-6.1%1.3%
Property, Plant & Equipment i1.86M1.64B

Cash Flow Statement Comparison

MetricNOVELIX (2025)ENTERO (2025)
Operating Cash Flow i-221.35M-1.78B
Operating Cash Flow % of Revenue i-72.1%-3.5%
Capital Expenditures i-1.06M-103.73M
Free Cash Flow i-137.91M-881.80M
FCF Margin i-44.9%-1.7%
Debt Repayment iN/A-458.22M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNOVELIXENTERO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i21.09M43.51M
Float Shares i3.72M14.37M
% Held by Insiders i70.63%65.97%
% Held by Institutions i0.00%12.55%
% Held by Public i29.37%21.48%

Dividend Analysis & Yield Comparison: NOVELIX PHARMACEUTICALS LIMITE vs Entero Healthcare Solutions

MetricNOVELIXENTERO
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A